When bleeds happen, NovoSeven® RT provides your patients with:
2-5
5
minutes
hours
Rapid reconstitution1
Rapid administration1
Rapid bleed control3
16ϫ less infusion volume
than pd-aPCC1,4,b
Up to 18ϫ faster to infuse
than pd-aPCC1,4,b,c
Helps control joint bleeds
in as few as 5 hoursd,e
Products scaled
proportionally
from actual size.
Ask your local Novo Nordisk Representative for a free NovoSeven® RT Patient Starter Kit
Find your Rep at NovoSevenRT.com/hcp
Important Safety Information (cont’d)
Warnings and Precautions (cont’d)
• Exercise caution when administering NovoSeven® RT to patients with an increased risk of thromboembolic
complications, such as those with disseminated intravascular coagulation (DIC), advanced atherosclerotic disease, crush
Print-only content
injury, septicemia, uncontrolled post-partum hemorrhage, history of coronary heart disease, liver disease,
post-operative immobilization, in elderly patients, in neonates, or in patients receiving concomitant treatment
with aPCCs/PCCs (activated or nonactivated prothrombin complex concentrates).
• Hypersensitivity reactions, including anaphylaxis, have been reported with NovoSeven® RT. Administer only if clearly
needed in patients with known hypersensitivity to NovoSeven® RT, any of its components, or mouse, hamster, or
bovine proteins. Should symptoms occur, discontinue NovoSeven® RT and administer appropriate treatment.
• Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C).
If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the
recommended doses, anti